ClinicalTrials.gg
RecruitingNCT07163299ICE-MAGUpdated Nov 12, 2026

Intra-arterial Selective Hypothermic Magnesium Sulfate Infusion in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke

A Phase 1/2 interventional study of Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml). and Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml). in Acute Ischemic Stroke, sponsored by Capital Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Capital Medical University · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.
Updated Nov 12, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 45 studies in Ischemic Stroke by Capital Medical University — 20 open to participants now, 25 under way, 10 of them phase 3. Ischemic Stroke · Capital Medical University.

Planned enrollment
30th of 39
42 · median 208
Started
2025
with 9 others
Phase 1/2
2 of 45
1 open now
Primary completion
2026-12
later than 11 of 24 live
Registered
32nd of 45
by date

Among the 45 studies in Ischemic Stroke by Capital Medical University, this one is the 30th largest by planned enrollment of the 39 interventional ones that give a count, is one of 10 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 11 of the 24 other live ones, and was the 32nd registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

20 of the 45 studies in Ischemic Stroke by Capital Medical University are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Ischemic Stroke by Capital Medical University, or all of them as a file.
02

Study summary

The primary objective of this study is to estimate the safety and effectiveness of selective intra-arterial hypothermic magnesium sulfate infusion after endovascular thrombectomy in patients with acute ischemic stroke.

Addendum regarding phase 1 dosing implementation and planned phase 2 design:

This integrated phase 1/2 trial originally planned weight-individualized magnesium perfusate calculated as Target Mg (μmol/mL) = 0.6 × patient body weight. During phase 1 recruitment, no dedicated emergency pharmacy fast-track compound workflow existed for urgent EVT procedures, which would cause reperfusion delay if individualized mixing was performed intraoperatively. Therefore, a uniform fixed magnesium concentration of 20.29 mmol/L was adopted as a temporary operational solution for all 9 phase 1 participants, with dose escalation only performed by increasing total infusion volume (350/500/650 mL). For the upcoming phase 2 cohort, we will retain the fully safe 650 mL maximum infusion volume and conduct independent magnesium concentration escalation across six ascending tiers: 20.29, 22.54, 25.36, 28.98, 33.81, and 40.57 mmol/L. These concentrations are prepared by diluting the standard 5 g magnesium stock into 1000 mL, 900 mL, 800 mL, 700 mL, 600 mL, and 500 mL pre-cooled normal saline respectively. After defining the maximum tolerated magnesium concentration tier, the original weight-tailored compounding formula will be fully implemented for subsequent efficacy cohorts. All protocol adjustments have received institutional review board amendment approval.

Read the detailed description

Protocol Deviation \& Planned Phase 2 Adjustment Statement The pre-specified weight-based magnesium dilution strategy could not be executed during phase 1 due to lack of on-demand intraoperative pharmacy preparation capacity for hyperacute stroke patients. All 9 phase 1 subjects received standardized cold perfusate with a fixed magnesium concentration of 20.29 mmol/L (5g MgSO₄·7H₂O diluted into 1000 mL 4℃ saline), with volumetric escalation (350/500/650 mL) only, without varying magnesium concentration. This temporary fixed-concentration regimen was a pragmatic emergency workflow compromise, not the permanent trial dosing design.

In phase 2 of this integrated registered trial, the validated safe upper limit of 650 mL total infusion volume will be fixed to avoid intracranial fluid overload. We will first conduct single-variable magnesium concentration escalation across six sequential ascending tiers:

20.29 mmol/L (5 g stock diluted in 1000 mL 0.9% saline) 22.54 mmol/L (5 g stock diluted in 900 mL 0.9% saline) 25.36 mmol/L (5 g stock diluted in 800 mL 0.9% saline) 28.98 mmol/L (5 g stock diluted in 700 mL 0.9% saline) 33.81 mmol/L (5 g stock diluted in 600 mL 0.9% saline) 40.57 mmol/L (5 g stock diluted in 500 mL 0.9% saline) After establishing a tolerable magnesium concentration threshold and identifying the maximum tolerated dose, the original registry-specified weight-individualized compounding method (Target Mg = 0.6 μmol/mL × patient body weight) will be fully applied for efficacy evaluation cohorts. This amendment was reviewed and formally approved by the institutional review board (Amendment No.XYFY2025-KL360-02).

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • thrombectomy
  • magnesium sulfate
  • intra-arterial hypothermic
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age range of 18-80 years old (including critical value);
  2. No gender restrictions;
  3. The clinical diagnosis is acute ischemic stroke of the anterior circulation, and the site of acute occlusion of the responsible vessel is located in the intracranial segment of the internal carotid artery and the M1 or M2 segment of the middle cerebral artery;
  4. The symptoms and signs are consistent with acute anterior circulation ischemic stroke, NIHSS≥6;
  5. The time from onset to endovascular thrombectomy of acute ischemic stroke is within 24 hours;
  6. Indications for endovascular thrombectomy of acute ischemic stroke: ① ASPECTS score ≥ 6 points, within 6 hours of onset; ② 6-16 hours after onset, meeting DEFUSE-3 criteria (infarct core volume \< 70 mL, mismatch rate ≥ 1.8 and mismatch volume > 15 mL) or DAWN criteria (NIHSS ≥ 10 and infarct core volume \< 31 mL); Or NIHSS ≥ 20 and infarct volume 31-51 mL); ③ Within 16-24 hours of onset, meet DAWN criteria (NIHSS ≥ 10 points and infarct core volume \< 31mL); Or NIHSS ≥ 20 points and infarct volume 31-51 mL)
  7. The mRS score before stroke is 0-1 points;
  8. Written provided by the patients or their legal relatives.

Exclusion criteria

Exclusion Criteria:

General exclusion criteria:

  1. Clinical manifestations suggest the presence of intracranial cerebral parenchymal hemorrhage or subarachnoid hemorrhage (even if imaging results are normal);
  2. During a stroke, accompanied by epilepsy, an accurate NIHSS score cannot be obtained;
  3. Accompanied by coma or mental disorders, it may interfere with the assessment of neurological function;
  4. History of allergy to iodinated contrast agents or history of anaphylactic shock;
  5. Baseline blood glucose\<50mg/dL (2.78mmol) or>400mg/dL (22.20mmol);

    *Acceptable fingertip blood glucose results

  6. Baseline count\<50 × 10\^9/L;
  7. Recently (i.e. within 30 days prior to inclusion in the study), there has been a history of significant gastrointestinal or other bleeding; Active bleeding, abnormal coagulation factors, or bleeding tendency (taking anticoagulant drugs with ≥ 3 or PT ≥ 3 × ; if the researcher believes that the subject has no coagulation dysfunction, there is no need to wait for coagulation test results to determine whether to enroll);
  8. During a stroke, there may be fever or active infections that require systemic treatment (such as active pulmonary tuberculosis);
  9. History of chronic heart failure with criteria>1; Uncontrolled hypertension (systolic blood pressure>180mmHg or diastolic blood pressure>105mmHg after standardized treatment), hypotension (systolic blood pressure ≤ 100mmHg after standardized treatment), unstable angina, myocardial infarction, or bypass or stent surgery within 6 months;
  10. Accompanied by pulmonary diseases such as , tuberculosis, pneumonia, pneumothorax, atelectasis, pulmonary fibrosis, bronchopulmonary dysplasia, pleural effusion, acute respiratory distress syndrome, irregular breathing, etc;
  11. Severe liver and kidney dysfunction, including but not limited to: cirrhosis, hepatic encephalopathy, ascites, renal failure or uremia (Ccr\<25ml/min), hepatorenal syndrome, etc;
  12. Pregnant or lactating women;
  13. Patients with acute stroke within 48 hours after percutaneous cardiovascular and cerebrovascular intervention and major surgery;
  14. Currently participating in interventional clinical trials and using research drugs or medical devices;
  15. Participants may not be able to complete this study due to other reasons or may not be considered eligible for inclusion by the researchers;

Image exclusion criteria:

  1. CTA/MRA/DSA shows excessive vessel curvature, which may hinder the delivery of interventional instruments;
  2. Suspected cerebral vasculitis based on medical history and CTA/MRA/DSA;
  3. Suspected aortic dissection based on medical history and CTA/MRA/DSA;
  4. CTA/MRA/DSA confirmed multi vessel regional occlusion (such as bilateral anterior circulation or anterior/posterior circulation, extracranial carotid artery with intracranial tandem lesions), or clinical evidence of bilateral infarction or multi regional infarction;
  5. CTA/MRA/DSA confirms moyamoya disease or moyamoya syndrome;
  6. CT/MRI confirms significant effect of midline shift;
  7. CT/MRI confirms the presence of intracranial tumors (excluding small meningiomas);
  8. CT/MRI confirms the presence of intracranial hemorrhage.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Selective intra-arterial hypothermic magnesium sulfate infusion of low volume

    Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml). Note: In phase 1, all participants in these three volume-escalation arms received a uniform fixed-concentration perfusate of 20.29 mmol/L (5 g magnesium sulfate stock diluted into 1000 mL pre-cooled saline). Weight-tailored perfusate originally specified in registry could not be implemented due to absence of emergency pharmacy fast-track compounding workflow.

    Procedure: Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml).

  • Experimental
    Selective intra-arterial hypothermic magnesium sulfate infusion of moderate volume

    Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml). Note: In phase 1, all participants in these three volume-escalation arms received a uniform fixed-concentration perfusate of 20.29 mmol/L (5 g magnesium sulfate stock diluted into 1000 mL pre-cooled saline). Weight-tailored perfusate originally specified in registry could not be implemented due to absence of emergency pharmacy fast-track compounding workflow.

    Procedure: Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml).

  • Experimental
    Selective intra-arterial hypothermic magnesium sulfate infusion of high volumn

    Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (650 ml). Note: In phase 1, all participants in these three volume-escalation arms received a uniform fixed-concentration perfusate of 20.29 mmol/L (5 g magnesium sulfate stock diluted into 1000 mL pre-cooled saline). Weight-tailored perfusate originally specified in registry could not be implemented due to absence of emergency pharmacy fast-track compounding workflow.

    Procedure: Endovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (650 ml).

  • Sham comparator
    Control

    Endovascular thrombectomy alone

    Procedure: Endovascular thrombectomy

  • Experimental
    Phase 2 Fixed-Volume Concentration-Escalation Cohort

    Intra-arterial selective cooling magnesium sulfate perfusate. All subjects receive a fixed maximum total infusion volume of 650 mL. Six ascending magnesium concentration tiers will be tested sequentially: 20.29 mmol/L, 22.54 mmol/L, 25.36 mmol/L, 28.98 mmol/L, 33.81 mmol/L, and 40.57 mmol/L. Each concentration is prepared by diluting one 5 g/10 mL magnesium sulfate heptahydrate stock vial into 1000 mL, 900 mL, 800 mL, 700 mL, 600 mL, or 500 mL pre-cooled 4 °C normal saline, respectively. After identifying the maximum tolerated magnesium concentration, the original registry-specified weight-individualized compounding formula will be implemented for subsequent efficacy-focused cohorts. This phase is enrolling participants.

    Procedure: Phase 2 Fixed-Volume Concentration-Escalation Cohort

Interventions

  • ProcedureEndovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (350 ml).

    According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 350 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min. Note: The pre-planned weight-tailored magnesium solution could not be prepared intraoperatively in phase 1 due to unavailable emergency pharmacy workflow. All 9 patients received uniform 20.29 mmol/L perfusate, with only infusion volume escalated.

  • ProcedureEndovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (500 ml).

    According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 500 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min. Then pause for 5 min, followed by another 5 min of infusion at the original rate.Note: The pre-planned weight-tailored magnesium solution could not be prepared intraoperatively in phase 1 due to unavailable emergency pharmacy workflow. All 9 patients received uniform 20.29 mmol/L perfusate, with only infusion volume escalated.

  • ProcedureEndovascular thrombectomy combination with selective intra-arterial hypothermic magnesium sulfate infusion (650 ml).

    According to patient's weight, magnesium sulfate (MgSO4) will be diluted to 650 ml 4°C saline solution (0.6μmol/kg/ml). During the thrombectomy procedure, a micro-catheter will be advanced until it reaches beyond the clot responsible for the ischemic symptoms, then cold 50 ml MgSO4 solution will be infused into the ischemic territory at 10 ml/min through the micro-catheter. After that, thrombectomy with a stent retriever will be performed to recanalize the occluded vessel as soon as possible. Immediately after successful thrombectomy, cold MgSO4 solution will be re-infused into the ischemic brain tissue through the catheter at a rate of 30 ml/min for 10 min. Then pause for 5 min, followed by intermittent infusion at the original rate for another 5 min twice. The interval between two times is also 5 min.Note: The pre-planned weight-tailored magnesium solution could not be prepared intraoperatively in phase 1.All 9 patients received uniform 20.29 mmol/L perfusate.

  • ProcedureEndovascular thrombectomy

    Endovascular thrombectomy

  • ProcedurePhase 2 Fixed-Volume Concentration-Escalation Cohort

    This phase 2 cohort uses a fixed 650 mL maximum infusion volume with six ascending magnesium concentrations: 20.29, 22.54, 25.36, 28.98, 33.81, 40.57 mmol/L. Each tier is mixed by diluting one 5 g magnesium stock into 1000/900/800/700/600/500 mL pre-cooled saline. After confirming safe magnesium levels, we will adopt the registry's weight-based formulation. Infusion protocols match phase 1, and this two-stage design is approved under IRB amendment No.XYFY2025-KL360-02

06

What researchers measure

Primary outcomes

  1. Mortality at 90 days

    Time frame: 90 days after intra-arterial hypothermic magnesium sulfate infusion

  2. Effectiveness evaluation indicators:

    Percentage of subjects with 90 days of functional independence (defined as mRS 0-2) (%) Evaluation time: 90 d (±14 d) after surgery

    Time frame: 90 days after intra-arterial hypothermic magnesium sulfate infusion

Secondary outcomes

  1. Grade 3-5 Treatment Emergent Adverse Event (TEAE) related to intervention occurring during treatment period

    TEAE includes but not limited to cardiovascular system response, abnormal electrocardiogram, water-electrolyte imbalance, core temperature decreasing, vascular spasm, shiver, infect, disturbance of consciousness.

    Time frame: Within 72 hours after intra-arterial hypothermic magnesium sulfate infusion

  2. All Treatment Emergent Adverse Event (TEAE) related to intervention occurring during treatment period

    Time frame: Within 72 hours after intra-arterial hypothermic magnesium sulfate infusion

  3. All Treatment Emergent Adverse Event (TEAE) occurring during treatment period

    Time frame: Within 72 hours after intra-arterial hypothermic magnesium sulfate infusion

  4. The proportion of symptomatic/asymptomatic intracranial hemorrhage within 24 hours

    Time frame: Within 24 hours after intra-arterial hypothermic magnesium sulfate infusion

  5. No reflow rate

    No reflow rate, defined as the percentage of subjects with a decrease in CBV or CBF by more than 15% compared to the contralateral side at 24 hours after treatment (%)

    Time frame: 24 hours (±6 hours) after surgery

  6. Cerebrospinal fluid parameters

    The levels of Mg²⁺, glutamate, NFL, MMP-9, inflammatory factors, as well as the metabolomics/proteomics of cerebrospinal fluid, are used to verify the central nervous system protection mechanism

    Time frame: 24 hours-7 day

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

Of 27 phase 1/2 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 9, 2025
StartActual
Sep 15, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Mar 30, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Recruiting
changed Nov 12, 2026
Sites
Affiliated Hospital of Xuzhou Medical University is now Recruiting
Nov 12, 2026
Contact
Study contact now listed: added j•••@ccmu.edu.cn · •••8952. See the current contact
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Enrolling by invitation→Recruiting
    Affiliated Hospital of Xuzhou Medical University is now Recruiting
    Contact Study contact now listed: added j•••@ccmu.edu.cn · •••8952. See the current contact
    + 1 other change: arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07163299
Collaborators
The Affiliated Hospital of Xuzhou Medical University
Responsible party
Ji Xunming,MD,PhD (Professor of Neurology, Xuanwu Hospital, Capital Medical University, Capital Medical University) — Principal investigator
First posted
Sep 9, 2025
Start date
Sep 15, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Xunming Ji, MD, PhD
Contact
jixm@ccmu.edu.cn
010-83198952

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion